Unichem Laboratories Ltd. Share Price

Unichem Labs reports five USFDA observations

Unichem Laboratories Limited

said a US Food and Drug Administration inspection at its Goa formulation facility concluded with five observations. The inspection at the Pilerne facility ran from September 21 to September 26, 2026. The observations were related to procedural enhancements, according to the company’s update. The number of observations alone does not establish the inspection’s full regulatory outcome. The nature of each observation and the company’s response will matter in assessing any operational implications. What I’m watching: Unichem’s response and any further regulatory communication regarding the Goa facility. Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing.

See More

Unichem Laboratories gets 5 USFDA observations at Goa

Unichem Laboratories got five USFDA observations at its Goa plant. Key levels: support near ₹482, resistance at ₹600, 52-week high at ₹687. Unichem Laboratories Limited [

] is likely to remain in focus today after the US Food and Drug Administration (USFDA) completed an inspection of the company’s Goa formulation facility at Pilerne between September 21 and 26, 2026. The inspection concluded with five observations, primarily related to procedural enhancements. Why it matters: the Goa plant, built in 1997, serves export markets, so USFDA outcomes are tracked. The final outcome will depend on the company's response and the regulator's assessment. The stock closed at ₹549.70 on September 25, down 0.53%. It is up about 25% in calendar 2026 so far. The market cap is ₹3,874 crore, and the P/E is 12.71 against a sector P/E of 30.84. Technically, the price has been moving between ₹482 and ₹600 since August. Support is near ₹482, immediate resistance is at ₹600, and the 52-week high of ₹687 is the major resistance above it. Volume has been low in this range. My view is neutral. Price is still inside its range. I will watch for a close above ₹600 or below ₹482 with volume. I do not hold this stock. Disclaimer: I, Akhilesh Jat (SEBI RA Reg. No. INH000016649), do not hold any position in the stock discussed. This content is informational, not a recommendation. Investments in securities are subject to market risks. Read all related documents carefully before investing.

See More

Dividend Stock Alert: Rs 100 per share payout by this iron

Abex Alloy Products Limited has fixed September 2, 2026 as the record date to determine shareholders eligible to receive the company’s recommended dividend of Rs 100 per share. The announcement comes after the company reported a strong performance in the first quarter, with net profit rising 30.5 per cent year-on-year to Rs 7.25 crore. The total dividend comprises a final equity dividend of Rs 40 per share, equivalent to 400 per cent of the face value, and a special dividend of Rs 60 per share, equivalent to 600 per cent of the face value. The special dividend is linked to the disposal of an investment property in Thane. Shareholders holding the company’s equity shares on the record date will be eligible for the dividend. The payout will be made on or after September 16, 2026, subject to approval at the company’s upcoming Annual General Meeting (AGM).

See More

Ipca Laboratories Ltd shares surged up to 12% on 17 August 2026,

Ipca Laboratories Ltd shares surged up to 12% on 17 August 2026, hitting a record high of ₹1,945 after reporting a 72% jump in quarterly profit and upgrading FY27 growth guidance. Brokerages including JM Financial, Nuvama, and Prabhudas Lilladher raised their target prices to ₹2,000–₹2,118, maintaining a ‘Buy’ rating. 📊 Q1 FY27 Financial Highlights Metric Q1 FY27 (June 2026) YoY Change Notes Revenue ₹ 2,788.10 crore +21% Strong domestic & export growth EBITDA ₹ 637.94 crore +50% Margin expanded 600 bps to 24% Net Profit (PAT) ₹ 401.89 crore +72% Driven by branded formulations & API EPS ₹ 15.84 +72% Analysts expected ₹ 12.43 — beat estimates Domestic formulations grew 13% YoY, branded generics 16%, and API exports 33%. The institutional export business doubled to ₹ 120 crore, though ₹ 40 crore was deferred from March shipments. 📈 Guidance & Outlook Revenue growth FY27: Raised to 14–16% (from 12–13%). EBITDA margin FY27: Upgraded to 23% (from 22%). US growth: Expected 15–17% with 7–8 new launches via Unichem subsidiary. FY29 target: Consolidated EBITDA margin 25–26%. Valuation: Trading at ~25× FY28E P/E; brokerages see scope for further re‑rating. 🧪 Segment Performance India Business: ₹ 1,082 crore revenue (+13% YoY). Export Business: Up 34% YoY; Europe grew ~70%. API Segment: Strong recovery in both domestic and export markets. Unichem Laboratories: Maintains 10% growth guidance and 13% EBITDA margin. 💹 Brokerage Ratings (17 Aug 2026) Brokerage Rating Target Price Key Comment JM Financial Buy ₹ 2,118 “Margins set to improve to 25–26% mid‑term.” Nuvama Institutional Equities Buy ₹ 2,025 “Strong mix change and operating leverage to drive profitability.” Prabhudas Lilladher Buy ₹ 2,000 “Recovery in API segment and steady domestic growth support valuation.”

See More

Unichem Laboratories Focuses on Specialty Portfolio and International Growth

Unichem Laboratories continues to strengthen its pharmaceutical business through branded formulations, active pharmaceutical ingredients (APIs), and regulated market exports. The company is focusing on expanding its specialty portfolio, improving manufacturing efficiency, and enhancing its presence across domestic and international markets. Investments in product development, regulatory compliance, and quality systems support long-term growth opportunities. Investors are closely monitoring new product launches, export performance, capacity utilization, regulatory approvals, operating margins, and cash flow generation as key indicators of the company’s operational performance. Disclaimer: Investments in securities are subject to market risks. This content is for educational purposes only. Investors must verify information before investing and consider their financial position and risk profile. Please read the full disclosure and disclaimer in the relevant official documents before making any investment decision.

See More

Unichem Laboratories Ltd – Fundamental Analysis

Unichem Laboratories Ltd is an established Indian pharmaceutical company engaged in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), generic formulations, and contract manufacturing services. The company has been strengthening its global business by expanding its generics portfolio, increasing exports, and enhancing contract manufacturing capabilities. Financially, Unichem Laboratories has maintained a healthy balance sheet with relatively low debt and stable cash generation. Revenue growth has improved over recent years, supported by higher exports and stronger manufacturing utilization. While profitability has shown recovery, earnings may fluctuate due to regulatory expenses, product mix, and investments in research and manufacturing expansion. One of the company's biggest strengths is its diversified pharmaceutical portfolio, internationally approved manufacturing facilities, and presence in regulated export markets. However, investors should monitor regulatory inspections, pricing pressure in global generic markets, competition from domestic and international pharmaceutical companies, and fluctuations in raw material costs. Delays in product approvals or adverse regulatory observations could also impact future growth and profitability. Overall, Unichem Laboratories Ltd appears to be a fundamentally sound pharmaceutical company with improving operational performance, a diversified product portfolio, and strong long-term growth potential. Its expanding export business, manufacturing capabilities, and exposure to the growing global generics market make it an attractive long-term investment, although regulatory and competitive risks remain important factors to monitor.

See More